摘要
目的 探讨草分枝杆菌F.U.36注射液辅助含环丝氨酸方案治疗耐多药肺结核的临床疗效及对T淋巴细胞亚群的影响。方法 依据随机信封法将瑞金市人民医院2018年6月-2021年6月60例耐多药肺结核患者分为对照组(n=30,含环丝氨酸方案治疗)和观察组(n=30,含环丝氨酸方案联合草分枝杆菌F.U.36注射液治疗)。比较两组临床疗效、炎性因子、T淋巴细胞亚群及免疫功能,并统计两组治疗期间不良反应发生情况。结果 观察组临床总有效率高于对照组(P<0.05)。治疗后,观察组炎性因子、T淋巴细胞亚群及免疫功能水平改善均优于对照组(P<0.05)。两组治疗期间不良反应总发生率比较差异无统计学意义(P>0.05)。结论 草分枝杆菌F.U.36注射液辅助含环丝氨酸方案治疗耐多药肺结核可提高治疗效果,降低IL-6、TNF-α、CRP水平,同时能够改善T淋巴细胞亚群及免疫功能,且不会增加不良反应。
Objective To explore the clinical efficacy of mycobacterium phlei F.U.36 injection assisted with cycloserine regimen in the treatment of multidrug-resistant pulmonary tuberculosis and its effect on T lymphocyte subsets.Methods According to the random envelope method,60 patients with multidrug-resistant pulmonary tuberculosis at Ruijin People's Hospital from June 2018 to June 2021 were divided into a control group(n=30,treated with cycloserine regimen)and an observation group(n=30,treated with cycloserine regimen and mycobacterium phlei F.U.36 injection).The clinical efficacy,inflammatory factors,T lymphocyte subsets and immune function were compared between the two groups,and the incidence of adverse reactions during treatment was counted.Results The total clinical effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the observation group showed better improvement in inflammatory factors,lung function,T lymphocyte subsets and immune function compared to the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two treatment groups(P>0.05).Conclusion Mycobacterium phlei F.U.36 injection assisted with cycloserine regimen in the treatment of multidrug-resistant pulmonary tuberculosis can improve treatment efficacy,reduce the levels of IL-6,TNF-αand CRP,and improve lung function,T lymphocyte subsets and immune function without increasing adverse reactions.
作者
杨泉
YANG Quan(Ruijin People's Hospital,Ruijin Jiangxi 342599,China)
出处
《药品评价》
CAS
2024年第2期227-231,共5页
Drug Evaluation
关键词
耐多药肺结核
草分歧杆菌
含环丝氨酸
疗效
T淋巴细胞
Multidrug-resistant pulmonary tuberculosis
Mycobacterium phlei
Cycloserine regimen
Efficacy
T lymphocytes
